Bladder Cancer


This study is designed to test the safety and potential benefit of adding an existing drug used for bone protection (denosumab) to a new immune stimulating drug (pembrolizumab).

Trial overview


Metastatic kidney cancer


Denosumab and Pembrolizumab in clear cell renal carcinoma: a phase II trial (ANZUP1601) KidnEY cancer Pembrolizumab And Denosumab.

Eligibility criteria

  • Kidney Cancer after progression on first line treatment
  • No prior treatment with immunotherapy

Study details

The treatment is 3 weekly Pembrolizumab and Denosumab. While on treatment there will be regular blood tests and scans to monitor progress. At completion of treatment the study will continue to follow your progress.

Further information

For more information regarding this clinical trial click here.


Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.